Elan Developing Antegren For Chronic MS; Quarterly Sales Up 50%
Executive Summary
Elan will pursue development of Antegren (natalizumab) humanized monoclonal antibody for chronic treatment of multiple sclerosis, the company announced July 26.
You may also be interested in...
Biogen Believes Biologics Production Capacity Will Lure Partners
Biogen believes its investments in protein manufacturing capacity will give it an advantage in upcoming years in the search for new product partners in the biotech sector.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011